NGS-based proteomics platform with unprecedented depth.
Measurement of all forms of all proteins in all species.
High-Plex Proteomics
High-plex proteomics translates information about specific protein abundance into corresponding DNA abundance. In doing so, it effectively mirrors the approach used in transcriptomics. However, most existing high-plex proteomics systems have taken a bottom-up approach, identifying probes for individual proteins one at a time, and gradually building a probe array from these components.
At NeoVentures Biotechnology Europe, we are the only ones to have taken a more powerful and innovative approach by working from the top down. Rather than building probe arrays one protein at a time, we have instead developed a comprehensive platform, called the Aptamarker Platform, based on the application of the same 268 million Aptamarkers to every sample. Through this standardized and scalable method, we are able to characterize differential binding of these probes to potential biomarkers in biological fluids or tissues by leveraging next-generation sequencing (NGS) analysis. As a result, our approach offers a more efficient and reproducible path to high-plex proteomic profiling.
There are several advantages to our top-down approach:
- Greater depth of coverage 268 million probes versus several thousand with other platforms.
- Ease of use, we do not build arrays, and there is no need for specialized equipment to perform the Aptamarker analysis.
- High reproducibility, we are not using polyclonal antibodies.
- Capacity to characterize non-canonical in addition to canonical forms of proteins (post-translational modifications)
- Not limited by reference to human proteins.
- Clear path to Dx applications
Aptamarker Platform Workflow
Aptamarker Platform Applications
Preclinical patient stratification
Cross application from animal trials to humans.
Aptamarker are not subject to immune tolerance like antibodies. There will be higher number of orthologues across species.
Identification of new biomarkers and validation of existing ones
The discovery of new biomarkers is enabled by those Aptamarker frequency profiles that help explain the disease but are not correlated with existing biomarkers.
Assessment of treatment effect
Aptamarker structure patterns can predict outcomes from pre-treatment and treatment effects such as recovery and side effects. They be used as inclusion or exclusion criteria.
Drug development
The Aptamarker platform can elucidate different epitopes on target proteins. The loss of a set of structures for a specific epitope in the presence of treatment characterizes the binding site. Determine target kinetics, off-target binding, and patient to patient variance.
NeoVentures Biotechnology Europe's Vision
The Aptamarker Platform has the potential to fundamentally transform the nature of health care. At NeoVentures Biotechnology Europe, our vision is to enable personalized medicine in ways that were previously unimaginable. To achieve this, we believe that personalized health care must begin with personalized diagnosis. With this in mind, we are developing a platform that continuously learns and improves with every individual sample analyzed. To fully realize this potential, the integration of artificial intelligence and automation will be essential.
Ultimately, our goal is to monitor the frequency of all biomolecules present in the blood, compare these to each individual’s unique baseline, and detect any deviation that may indicate early signs of disease or dysfunction. In this context, our platform is the first to make such a forward-looking vision both imaginable and feasible.
Therefore, we are actively seeking investors and partners who are committed to driving sustainable advancements in existing health care systems. At the heart of this transformation is a model that empowers individuals with the tools and information needed to manage their own health and wellness proactively.